At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BBH VanEck Biotech ETF
Trading 10-29 15:24:14 EDT
254.92
+1.64
+0.65%
High257.70Low254.18Vol10.43K
Open256.11D1 Closing253.27Amplitude1.39%
Mkt Cap516.59MTradable Cap516.59MTotal Shares2.03M
T/O2.67MT/O Rate0.51%Tradable Shares2.03M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Should Pancreatic Cancer Trial Progress Require Action From Revolution Medicines (RVMD) Investors?
Simply Wall St.  ·  10-29 21:40
Should Pancreatic Cancer Trial Progress Require Action From Revolution Medicines (RVMD) Investors?
Regeneron Pharma Price Target Raised to $922.00/Share from $875.00 by Canaccord Genuity
Dow Jones  ·  10-29 06:45
Regeneron Pharma Price Target Raised to $922.00/Share from $875.00 by Canaccord Genuity
Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Reports Sale of $431,946.90 in Common Shares
Reuters  ·  10-29 06:00
Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Reports Sale of $431,946.90 in Common Shares
Amgen Sets Third-Quarter Results Webcast
Reuters  ·  10-29 05:07
Amgen Sets Third-Quarter Results Webcast
Analysts Offer Insights on Healthcare Companies: Icon (ICLR), Centene (CNC) and Gilead Sciences (GILD)
TIPRANKS  ·  10-28 21:40
Analysts Offer Insights on Healthcare Companies: Icon (ICLR), Centene (CNC) and Gilead Sciences (GILD)
Research Organization IAVI Receives US Funding for Ebola Vaccine Development
Reuters  ·  10-28 21:00
Research Organization IAVI Receives US Funding for Ebola Vaccine Development
Enanta Pharmaceuticals CEO Jay Luly Announces Retirement by February 1, 2027
Reuters  ·  10-28 19:05
Enanta Pharmaceuticals CEO Jay Luly Announces Retirement by February 1, 2027
Regeneron Pharmaceuticals, Inc. : Canaccord Genuity Raises Target Price to $922 from $875
THOMSON REUTERS  ·  10-28 17:26
Regeneron Pharmaceuticals, Inc. : Canaccord Genuity Raises Target Price to $922 from $875
Sino Biopharmaceutical Stock Rallies 2.0% in Hong Kong, Outperforms Competitors
Dow Jones  ·  10-28 16:31
Sino Biopharmaceutical Stock Rallies 2.0% in Hong Kong, Outperforms Competitors
Amgen Announces 2026 Fourth Quarter Dividend
THOMSON REUTERS  ·  10-28 06:28
Amgen Announces 2026 Fourth Quarter Dividend
Amgen - Declares Q4 2026 Dividend of $2.52 Per Share
THOMSON REUTERS  ·  10-28 06:28
Amgen - Declares Q4 2026 Dividend of $2.52 Per Share
Press Release: AMGEN Announces 2026 Fourth Quarter Dividend
Dow Jones  ·  10-28 06:28
Press Release: AMGEN Announces 2026 Fourth Quarter Dividend
Revolution Medicines Participates in Guggenheim and Jefferies Healthcare Conferences
Reuters  ·  10-28 04:15
Revolution Medicines Participates in Guggenheim and Jefferies Healthcare Conferences
Beta Bionics Q3 Adjusted Ebitda Misses Estimates
Reuters  ·  10-28 04:11
Beta Bionics Q3 Adjusted Ebitda Misses Estimates
Revolution Medicines to Participate in November 2026 Investor Conferences
GlobeNewswire  ·  10-28 04:05
Revolution Medicines to Participate in November 2026 Investor Conferences
Amgen Study Finds Bone Marrow Immune Cells Can Enter Aging Brain
Reuters  ·  10-28 03:43
Amgen Study Finds Bone Marrow Immune Cells Can Enter Aging Brain
FDA says Amgen’s video ads for Vectibix ‘false or misleading’
TIPRANKS  ·  10-28 03:20
FDA says Amgen’s video ads for Vectibix ‘false or misleading’
FDA Terms Amgen's Vectibix Promotional Video Misleading, Orders Ceasure of Communications
Reuters  ·  10-28 02:29
FDA Terms Amgen's Vectibix Promotional Video Misleading, Orders Ceasure of Communications
FDA Warns Amgen over Cancer Drug Promotional Video
Reuters  ·  10-28 02:25
FDA Warns Amgen over Cancer Drug Promotional Video
FDA: Amgen Ordered to Cease Misleading Vectibix Promotional Communications; Faces Seizure and Injunction if Violations not Corrected
THOMSON REUTERS  ·  10-28 01:34
FDA: Amgen Ordered to Cease Misleading Vectibix Promotional Communications; Faces Seizure and Injunction if Violations not Corrected

Introduction

Company Name.
VanEck Biotech ETF
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Issue price:
--